From each FDA label

What do GLP-1s interact with?

8 of the 10 labels warn that insulin or sulfonylureas taken with the medicine raise the risk of low blood sugar. 8 say a slower stomach can change how oral medicines are absorbed. Wegovy and Rybelsus/Ozempic tablets also report levothyroxine exposure 33% higher in a study with semaglutide tablets.

Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Aug 28, 2026.

Word for word

What each label says about drug interactions

Sentences from each label, in its own words. Only cross-references are removed.

Wegovy

  • Wegovy lowers blood glucose and can cause hypoglycemia.
  • The risk of hypoglycemia is increased when Wegovy is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylureas).
  • The addition of Wegovy in patients treated with insulin has not been evaluated.
  • When initiating Wegovy, consider reducing the dose of concomitantly administered insulin secretagogue or insulin to reduce the risk of hypoglycemia.
  • Wegovy causes a delay of gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications.
  • In clinical pharmacology trials with semaglutide 1 mg once weekly injection, semaglutide did not affect the absorption of orally administered medications.
  • In a drug interaction study with the semaglutide tablet, levothyroxine exposure was increased 33% (90% CI: 1.25-1.42).
  • Monitor the effects of oral medications concomitantly administered with Wegovy.

Label revised Jun 18, 2026. DailyMed

Ozempic

  • Ozempic stimulates insulin release in the presence of elevated blood glucose concentrations.
  • Patients receiving Ozempic in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.
  • When initiating Ozempic, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.
  • Ozempic causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.
  • In clinical pharmacology trials, semaglutide did not affect the absorption of orally administered medications to any clinically relevant degree.
  • Nonetheless, caution should be exercised when oral medications are concomitantly administered with Ozempic.

Label revised Jun 1, 2026. DailyMed

Rybelsus and Ozempic tablets

  • Semaglutide stimulates insulin release in the presence of elevated blood glucose concentrations.
  • Patients receiving Rybelsus or Ozempic tablets in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.
  • When initiating Rybelsus or Ozempic tablets, consider reducing the dosage of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.
  • Semaglutide cause a delay of gastric emptying and thereby has the potential to impact the absorption of other oral drugs.
  • Levothyroxine exposure was increased 33% (90% CI: 1.25 to 1.42) when administered with semaglutide tablets in a drug interaction study.
  • When using Rybelsus or Ozempic tablets concomitantly with other oral drugs that have a narrow therapeutic index or that require clinical monitoring, consider increased clinical or laboratory monitoring.

Label revised Jan 30, 2026. DailyMed

Zepbound

  • When initiating Zepbound, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) to reduce the risk of hypoglycemia.
  • Zepbound delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications.
  • Caution should be exercised when oral medications are concomitantly administered with Zepbound.
  • Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with Zepbound.
  • Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with Zepbound and for 4 weeks after each dose escalation.
  • Hormonal contraceptives that are not administered orally should not be affected.

Label revised Aug 28, 2026. DailyMed

Mounjaro

  • When initiating Mounjaro, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia.
  • Mounjaro delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications.
  • Caution should be exercised when oral medications are concomitantly administered with Mounjaro.
  • Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with Mounjaro.
  • Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with Mounjaro.
  • Hormonal contraceptives that are not administered orally should not be affected.

Label revised Aug 27, 2026. DailyMed

Foundayo

  • The maximum dosage of Foundayo is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor.
  • Avoid concomitant use of Foundayo with strong CYP3A4 inhibitors that also inhibit OATP1B (e.g., ritonavir).
  • CYP3A4 inhibitors increase Foundayo exposure, which may increase the risk of Foundayo-associated adverse reactions.
  • Strong CYP3A4 inhibitors that also clinically inhibit OATP1B are expected to significantly increase plasma concentrations of Foundayo, which may increase the risk of Foundayo-associated adverse reactions.
  • Avoid concomitant use of Foundayo with strong CYP3A4 inducers.
  • Induction of CYP3A4 decreases Foundayo exposure, which may reduce the effectiveness of Foundayo.
  • Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 30 days after initiation with Foundayo and for 30 days after each dose escalation.
  • Hormonal contraceptives that are not administered orally should not be affected.

Label revised Jul 29, 2026. DailyMed

Trulicity

  • Trulicity delays gastric emptying and thus has the potential to reduce the rate of absorption of concomitantly administered oral medications.
  • The delay in gastric emptying is dose-dependent but is attenuated with the recommended dose escalation to higher doses of Trulicity.
  • The delay is largest after the first dose and diminishes with subsequent doses.
  • In clinical pharmacology studies, Trulicity 1.5 mg did not affect the absorption of the tested orally administered medications to a clinically relevant degree.
  • There is limited experience with the use of concomitant medications in clinical trials with Trulicity doses of 3 mg and 4.5 mg.
  • Monitor drug levels of oral medications with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with Trulicity.
  • When initiating Trulicity, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.

Label revised Jun 16, 2026. DailyMed

Saxenda

  • Saxenda causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.
  • In clinical pharmacology trials, liraglutide did not affect the absorption of the tested orally administered medications to any clinically relevant degree.
  • Nonetheless, monitor for potential consequences of delayed absorption of oral medications concomitantly administered with Saxenda.

Label revised Feb 25, 2026. DailyMed

Victoza

  • Victoza causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.
  • In clinical pharmacology trials, Victoza did not affect the absorption of the tested orally administered medications to any clinically relevant degree.
  • Nonetheless, caution should be exercised when oral medications are concomitantly administered with Victoza.
  • Victoza stimulates insulin release in the presence of elevated blood glucose concentrations.
  • Patients receiving Victoza in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.
  • When initiating Victoza, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.

Label revised Oct 14, 2025. DailyMed

Byetta

  • Exenatide promotes insulin release from pancreatic beta-cells in the presence of elevated glucose concentrations.
  • The risk of hypoglycemia is increased when exenatide is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin.
  • When initiating Byetta, consider reducing the dose of concomitantly administered insulin secretagogue or insulin to reduce the risk of hypoglycemia.
  • In a drug interaction study, Byetta did not have a significant effect on INR.
  • There have been postmarketing reports for Byetta of increased INR with concomitant use of warfarin, sometimes associated with bleeding.
  • In patients taking warfarin, the prothrombin time should be monitored more frequently after initiation or alteration of Byetta therapy.
  • For oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before Byetta injection.
  • If such drugs are to be administered with food, patients should be advised to take them with a meal or snack when Byetta is not administered.

Label revised Sep 2, 2025. DailyMed

Not from trials

Reports to FDA about drug interactions

Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.

MedicineReports namingAll reports on it
MounjaroDrug interaction: 46697,440
OzempicDrug interaction: 29170,863
TrulicityDrug interaction: 18487,279
WegovyDrug interaction: 18025,993
VictozaDrug interaction: 17641,462
ByettaDrug interaction: 12152,087
ZepboundDrug interaction: 11280,835
SaxendaDrug interaction: 617,270
Rybelsus and Ozempic tabletsDrug interaction: 567,758
FoundayoDrug interaction: 73,050

Counted through openFDA from FDA's Adverse Event Reporting System, refreshed weekly. One report can name several terms.

Updated automatically

Latest FDA label updates

Written from each source's own record as it changes. Every change on GLPcompare

Questions

Drug interactions on a GLP-1: common questions

What does Wegovy interact with?

Its FDA label: Wegovy lowers blood glucose and can cause hypoglycemia. The risk of hypoglycemia is increased when Wegovy is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylureas).

What does Ozempic interact with?

Its FDA label: Ozempic stimulates insulin release in the presence of elevated blood glucose concentrations. Patients receiving Ozempic in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.

What does Rybelsus interact with?

Its FDA label: Semaglutide stimulates insulin release in the presence of elevated blood glucose concentrations. Patients receiving Rybelsus or Ozempic tablets in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.

What does Zepbound interact with?

Its FDA label: When initiating Zepbound, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) to reduce the risk of hypoglycemia. Zepbound delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications.

What does Mounjaro interact with?

Its FDA label: When initiating Mounjaro, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia. Mounjaro delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications.

What does Foundayo interact with?

Its FDA label: The maximum dosage of Foundayo is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor. Avoid concomitant use of Foundayo with strong CYP3A4 inhibitors that also inhibit OATP1B (e.g., ritonavir).

What does Trulicity interact with?

Its FDA label: Trulicity delays gastric emptying and thus has the potential to reduce the rate of absorption of concomitantly administered oral medications. The delay in gastric emptying is dose-dependent but is attenuated with the recommended dose escalation to higher doses of Trulicity.

What does Saxenda interact with?

Its FDA label: Saxenda causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, liraglutide did not affect the absorption of the tested orally administered medications to any clinically relevant degree.

What does Victoza interact with?

Its FDA label: Victoza causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, Victoza did not affect the absorption of the tested orally administered medications to any clinically relevant degree.

Other side effects

Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.